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Abstract
Background: The understanding of the epidemiology of bronchiectasis is still affected by major limitations with
very few data published worldwide. The aim of this study was to estimate the epidemiological burden of
bronchiectasis in Italy in the adult population followed-up by primary care physicians.
Methods: This study analyzed data coming from a large primary care database with 1,054,376 subjects in the
period of time 2002–2015. Patients with bronchiectasis were selected by the use of International Statistical
Classification of Diseases, 9th revision, Clinical Modification codes (ICD-9-CM).
Results: Patients with bronchiectasis were more likely to have a history of tuberculosis (0.47% vs. 0.06%, p < 0.0001),
had higher rates of asthma (16.6% vs. 6.2%, p < 0.0001), COPD (23.3% vs. 6.4%, p < 0.0001) and rheumatoid arthritis
(1.9% vs. 0.8%, p < 0.0001). The prevalence and incidence of bronchiectasis in primary care in Italy in 2015 were 163
per 100,000 population and 16.3 per 100,000 person-years, respectively. Prevalence and incidence increased with
age and overall rates were highest in men over 75 years old. Prevalence and incidence computed after the
exclusion of patients with a diagnosis of either asthma or COPD is 130 per 100,000 and 11.1 cases per 100,000
person-years, respectively.
Conclusions: Bronchiectasis is not a rare condition in Italian adult population. Further studies are needed to
confirm our results and provide a better insight on etiology of bronchiectasis in Italy.
Trial registration: not applicable.
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Background
Bronchiectasis is a chronic respiratory syndrome follow-
ing a permanent dilation of the bronchi, associated with
the occurrence of cough, daily sputum production, and
recurrent respiratory infections [1]. The clinical syn-
drome is the final outcome of several genetic and ac-
quired medical conditions [2]. It has a substantial
healthcare and societal impact, mainly generated by fre-
quent hospitalizations and mortality [3, 4].
A large clinical and epidemiological heterogeneity can
be found across continents and among countries within
the same continent. Currently, the epidemiological bur-
den of the disease is partially unknown with only cross-
sectional and retrospective studies been published until
now (based in the USA and a few European countries)
[5–9]. Furthermore, data sources are medical insurance
or hospital discharge databases, or partially representa-
tive ad hoc population-based studies [3, 4, 6, 7].
Old-fashioned epidemiological reports highlighted
bronchiectasis as a rare disease. On the contrary, a re-
cent UK longitudinal study, based on primary care data,
showed an increase in annual incidence since 2004 [5].
It is reasonable to assume that bronchiectasis epidemi-
ology might be variable and local data would be needed
to define national policy priorities and to guide research
and development activities for new drugs. So far, no epi-
demiological studies have been conducted in Italy in in-
patient and outpatient settings.
In addition, the co-existence of bronchiectasis with
other obstructive pulmonary diseases, such as asthma
and chronic obstructive pulmonary diseases (COPD),
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might hinder the precise assessment of bronchiectasis
epidemiology; by now no studies have evaluated preva-
lence and incidence in a population of patients with only
bronchiectasis and no concomitant diagnosis of other
chronic respiratory diseases.
The aim of this study was to estimate the epidemio-
logical burden of bronchiectasis in Italy in the adult
(aged > 14 years) population followed-up by primary care
physicians, stratified by age and gender, both in overall
population and excluding patients with a concomitant
diagnosis of either asthma or COPD.
Methods
Data source
Data were retrieved from computer-based records in-
cluded in the Health Search IMS Health Longitudinal
Database (HSD). The HSD, which complies with the
European Union guidelines on the use of medical data
for research purposes, collected clinical records from
1996 to 2015. Patients recruited in the system had an
anonymous code linked to demographic information,
medical records, and date of death. Diseases were classi-
fied according to the International Classification of Dis-
ease, 9th revision, Clinical Modification (ICD-9-CM).
HSD population is comparable with the Italian popula-
tion surveyed by the Italian National Institute of Statis-
tics (ISTAT) for the following variables: gender, age, and
geographical location.
Study population
The study population included patients aged > 14 years
and followed-up up to 31 December 2015 by 800 Italian
general practitioners (GPs). They were detected with the
ICD9CM codes 494 and 011.5. The recruitment period
was from 1st January 2002 to 31st December 2015. Pa-
tients with diagnosis of ‘suspected bronchiectasis’ AND/
OR patients with diagnosis of cystic fibrosis were ex-
cluded. Since this study was based on open-access anon-
ymized data, approval from ethical committees was not
needed. Each case was matched up to ten controls, who
were randomly selected in the whole cohort, according to
sex, age, year of cohort entry and duration of follow-up.
Data collection
Primary outcomes included prevalence and incidence of
bronchiectasis in the Italian adult population. Clinical
characteristics were reported for all included patients.
Information on conditions associated with bronchiec-
tasis were also retrieved, including COPD (491.2; 493.2),
asthma (493.9), primary ciliary dyskinesia (759.3), tuber-
culosis (011.9), Kartagener syndrome (759.3), HIV infec-
tion (V08, 042), rheumatoid arthritis (714.0),
inflammatory bowel disease as ulcerative colitis (556.9)
and Crohn disease (555.9), bone marrow transplant
(41.0), hypogammaglobinemia (279.0), allergic broncho-
pulmonary aspergillosis ABPA (518.6), common variable
immunodeficiency (279.06), and alpha1-antitrypsin defi-
ciency (273.4).
Study definitions
The prevalence of bronchiectasis was estimated by cal-
culating the proportion of patients with a bronchiectasis
diagnosis from 1st January 2002 to 31st December 2015
to the adult population (per 100,000) with the 95% con-
fidence interval (95% CI). The annual incidence rate
from 2002 to 2015 was estimated by dividing new cases
of bronchiectasis to person-years with 95% CI according
to annual registration. A new case of bronchiectasis was
a patient with a new ICD diagnosis of bronchiectasis
without any similar diagnoses the years before. Both
prevalence and incidence estimates were stratified by
both gender and age classes each single year of analysis.
Sensitivity analysis was conducted to evaluate incidence
and prevalence estimates in patients with a diagnosis of
neither COPD nor asthma.
Results
Demographics and clinical characteristics of adult
patients with bronchiectasis
Mean (SD) age of patients with bronchiectasis was 67.5
(14.4) years, without any statistically significant differ-
ences in comparison with the control group (Table 1).
Patients with bronchiectasis were more likely to have a
history of tuberculosis (0.47% VS. 0.06%; P < 0.0001),
had higher prevalence of asthma (16.6% VS. 6.2%; P <
0.0001), COPD (23.3% VS. 6.4%; P < 0.0001), and
rheumatoid arthritis (1.9% VS. 0.8%; P < 0.0001), as sum-
marized in Table 1.
Prevalence and incidence of bronchiectasis in the Italian
adult population
A total of 1,054,376 subjects (543,974, 52%, females and
268,693, 25%, aged > 65 years) were included in the
Table 1 Conditions associated with bronchiectasis in our cohort
in 2015
Associated conditions Cases Controls p
History of tuberculosis 8 (0.47) 10 (0.06) < 0.0001
Asthma 285 (16.60) 1068 (6.22) < 0.0001
COPD 400 (23.26) 1099 (6.40) < 0.0001
HIV 0 (0) 17 (0.10) ns
Rheumatoid arthritis 33 (1.92) 135 (0.79) < 0.0001
Ulcerative colitis 9 (0.52) 69 (0.40) ns
Crohn disease 0 (0) 5 (0.03) ns
Hypogammaglobinemia 1 (0.06) 5 (0.03) ns
Common variable immunodeficiency 1 (0.06) 0 (0) ns
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database. Temporal trends of bronchiectasis incidence
and prevalence by gender are summarized in Fig. 1.
Prevalence increased in the overall study population,
rising from 62 in 2005 to 163 per 100,000 population in
2015. In the last year of the analysis, it was higher in
women than in men (178 VS. 147 per 100,000 popula-
tion, respectively). Prevalence also increased with age in
the overall population and in both males and females to
the highest rate of 466 cases per 100,000 population
(497 and 446 per 100,000 population in men and
women, respectively) in patients aged > 75 years. The in-
cidence of bronchiectasis in 2015 was 16.3 cases per 100,
000 person-years, with a higher rate among women
(18.2 VS. 14.1 per 100,000 person-years). Age was re-
lated to increased incidence, with a maximum rate of
42.9 per 100,000 person-years in patients aged 75–84
years (46.7 and 40.0 per 100,000 person-years in men
and women, respectively). Prevalence and incidence of
bronchiectasis by age group and gender is described in
Fig. 2.
Prevalence and incidence of bronchiectasis in adults
excluding patients with a diagnosis of either asthma or
COPD
In 2015, the prevalence was 130 cases per 100,000 popu-
lation, resulting higher in women than in men (140 VS.
110 per 100,000 population, respectively). Increasing age
was linked to increased prevalence both in the overall
population and in males and females up to the highest
rate of 350 cases per 100,000 population in patients > 75
A
B
Fig. 1 A Trend in annual prevalence of bronchiectasis by sex from 2005 to 2015. B Trend in annual incidence of bronchiectasis by sex from 2005
to 2015
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years (340 and 352 per 100,000 population in men and
women, respectively).
The incidence of bronchiectasis in 2015 was 11.1 cases
per 100,000 person-years, with higher rate in women
than men (12.7 VS. 9.4 per 100,000 person-years, re-
spectively). Incidence increased with aging up to a max-
imum rate of 28.9 per 100,000 person-years in patients
aged 75–84 years (29.0 in men and 28.8 in women). Data
are summarized in Figs. 3 and 4.
Discussion
Bronchiectasis overall prevalence in the Italian popula-
tion referring to GPs is 163 per 100,000 population,
whereas annual incidence is 16.3 per 100,000 person-
years. Both prevalence and incidence increase with age,
with the highest rates reported in patients aged > 75
years. Prevalence and incidence computed after the ex-
clusion of patients with a diagnosis of either asthma or
COPD is 130 per 100,000 and 11.1 person-years,
respectively.
This study provides the first epidemiological report on
bronchiectasis in Italy, showing that it is not a rare dis-
ease. Italian estimates seem similar to other European
settings, ranked between the lower prevalence described
by Ringshausen et al. in Germany (67 cases per 100,000
population) and the higher UK prevalence (566 and 485
new cases per 100,000 population in women and men,
respectively) [5, 7]. Interestingly, Italian prevalence is
lower if compared with the only other bronchiectasis co-
hort recruited in Southern Europe. In 2012 Monteagudo
analyzed primary care medical reports of 5.8 million
people in Catalonia and reported on a prevalence of 362
patients per 100,000 population [8]. This inconsistency
might be related to several reasons, including different
data sources and algorithms for data collection; however,
geographical heterogeneity might have a key role, as
recently highlighted by Chandrasekaran [10]. A better
understanding of the epidemiological variability should
be achieved by the analysis of international multicentric
cohorts, recruited with the same methodology and using
the same clinical definitions.
While Italian bronchiectasis prevalence and incidence are
slightly higher in females across all age groups, different es-
timates were found in 2015 in people older than 75 years
(prevalence 511 VS. 484 per 100,000 population and inci-
dence 46.7 VS. 40.0 per 100,000 person-years in males and
females, respectively). The increased rates in males are con-
sistent with findings from similar studies and - as already
observed - might be attributed to the high proportion of
COPD patients in this age class [5, 8]. The analysis in pa-
tients without a concomitant diagnosis of COPD confirmed
this hypothesis, where it was found that females were more
prevalent in all age groups. Notably, in our dataset COPD
is the most prevalent (23.3%) condition related to bronchi-
ectasis. At present, though biological plausibility and epi-
demiological association has been reported, the definition
of COPD as a cause of bronchiectasis is not widely accepted
[11, 12]. A recent literature review showed conflicting bron-
chiectasis prevalence estimates in COPD populations, ran-
ging from 4 to 28%, partially explained by the enrollment of
different populations or different CT diagnostic criteria
[13]. While the interpretation of a simple co-existence or
co-morbidity between COPD and bronchiectasis still holds
a prominent position, it has been recently postulated that
these medical conditions might occur as an overlap syn-
drome (the acronym BCOS has been proposed) with pos-
sible consequences in terms of treatment and increased
mortality [14–16].
Annual prevalence of bronchiectasis increased from
2005 to 2015 in men and women, as well as in the
Fig. 2 Mean prevalence of bronchiectasis by age group and sex in Italy in 2015
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Fig. 4 Mean prevalence of bronchiectasis by age group and sex in Italy in 2015, excluding those with a diagnosis of either asthma or COPD
A
B
Fig. 3 A Trend in annual prevalence of bronchiectasis by sex from 2005 to 2015, excluding those with a diagnosis of either asthma or COPD. B
Trend in annual incidence of bronchiectasis by sex from 2005 to 2015, excluding those with a diagnosis of either asthma or COPD
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overall population and in population without asthma
and COPD, in agreement with previous findings [5, 6].
While some of bronchiectasis could still be post-
infective, this increase in incidence among elderly people
might be attributed to specific adult-onset etiologies,
that are becoming more and more prevalent in aged and
chronically-ill patients. However, the increasing trend
might be partly explained by the wider use of chest CT
scan, population ageing, as well as increased awareness
of bronchiectasis among respiratory physicians.
This study has both strengths and limitations. It provides
robust data on epidemiology of bronchiectasis in Italy; they
are collected from GPs and provide a real-life and
population-based overview. However, the use of ICD codes
and the retrospective study design are likely to underesti-
mate the real prevalence and incidence of the disease. In
addition, ICD codes analysis is not related to a reliable data
collection on the underlying etiology. Finally, although radi-
ology is needed for bronchiectasis diagnosis, we could not
prove if each diagnosis was supported by chest CT scan. As
a consequence, diagnosis accuracy might be limited.
In addition, the study design did not allow to investi-
gate risk factors for bronchiectasis development, but
only medical conditions associated with bronchiectasis
have been reported.
Conclusions
Bronchiectasis is not a rare condition in Italy. Our re-
sults are the first epidemiological report of bronchiec-
tasis prevalence in Italy and contribute to a better
assessment of bronchiectasis epidemiology in Southern
Europe. Additional analysis from national registries are
needed to confirm study findings and could provide in-
sights on bronchiectasis etiology in Italy.
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